Capture-SELEX: Selection Strategy, Aptamer Identification, and Biosensing Application

Lam, Sin Yu; Lau, Hill Lam; Kwok, Chun Kit

doi:10.3390/bios12121142

Cited by 22 publications

(5 citation statements)

References 152 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…To address this, methods have been developed to use solubilized target molecules, some of which involve affixing the oligos instead. One such method is Capture-SELEX, in which the ability of aptamers to change confirmation upon target binding can be used to remove target-binding aptamers from the surface they are affixed to, though this method is typically limited to small molecule targets [22]. Another approach is to have both the oligos and the target in solution.…”

Section: Aptamer Selectionmentioning

confidence: 99%

Therapeutic Applications of Aptamers

Santarpia,

Carnes

2024

Preprint

View full text Add to dashboard Cite

Affinity reagents, or target-binding molecules, are quite versatile and are major workhorses in molecular biology and medicine. Antibodies are the most famous and frequently used type and they have been used for a wide range of applications, including laboratory techniques, diagnostics, and therapeutics. However, antibodies are not the only available affinity reagents and they do have significant drawbacks, including laborious and costly production. Aptamers are one potential alternative that have a variety of unique advantages. They are single stranded DNA or RNA molecules that can be selected for binding to many targets including proteins, carbohydrates, and small molecules – for which antibodies typically have low affinity. There are also a variety of cost-effective methods for producing and modifying nucleic acids in vitro without cells, whereas antibodies typically require cells or even whole animals. While there are also significant drawbacks to using aptamers in therapeutic applications, including low in vivo stability, aptamers have had success in clinical trials for treating a variety of diseases and two aptamer-based drugs have gained FDA approval. Aptamer development is still ongoing, which could lead to additional applications of aptamer therapeutics, including antitoxins, and combinatorial approaches with nanoparticles and other nucleic acid therapeutics that could improve efficacy.

show abstract

Section: Aptamer Selectionmentioning

confidence: 99%

Therapeutic Applications of Aptamers

Santarpia,

Carnes

2024

Preprint

View full text Add to dashboard Cite

show abstract

“…To address this, methods have been developed to use solubilized target molecules, some of which involve affixing the oligos instead. One such method is Capture-SELEX, in which the ability of aptamers to change conformation upon target binding can be used to remove target-binding aptamers from the surface they are affixed to, though this method is typically limited to small molecule targets [ 22 ]. Another approach is to have both the oligos and the target in solution.…”

Section: Aptamer Selection and Productionmentioning

confidence: 99%

Therapeutic Applications of Aptamers

Santarpia,

Carnes

2024

IJMS

View full text Add to dashboard Cite

Affinity reagents, or target-binding molecules, are quite versatile and are major workhorses in molecular biology and medicine. Antibodies are the most famous and frequently used type and they have been used for a wide range of applications, including laboratory techniques, diagnostics, and therapeutics. However, antibodies are not the only available affinity reagents and they do have significant drawbacks, including laborious and costly production. Aptamers are one potential alternative that have a variety of unique advantages. They are single stranded DNA or RNA molecules that can be selected for binding to many targets including proteins, carbohydrates, and small molecules—for which antibodies typically have low affinity. There are also a variety of cost-effective methods for producing and modifying nucleic acids in vitro without cells, whereas antibodies typically require cells or even whole animals. While there are also significant drawbacks to using aptamers in therapeutic applications, including low in vivo stability, aptamers have had success in clinical trials for treating a variety of diseases and two aptamer-based drugs have gained FDA approval. Aptamer development is still ongoing, which could lead to additional applications of aptamer therapeutics, including antitoxins, and combinatorial approaches with nanoparticles and other nucleic acid therapeutics that could improve efficacy.

show abstract

“…18 Aptamers are short, single-stranded oligonucleotides that are obtained in vitro through a technique called systematic evolution of ligands by exponential enrichment (SELEX). 19,20 Due to their high specicity, excellent stability and lower immunogenicity, aptamers hold great potential in the eld of medical diagnosis. Through adaptive folding, aptamers develop unique secondary and tertiary structures, enabling them to specically identify a wide range of targets such as small molecules, metal ions, toxins, proteins, and entire cells.…”

Section: Introductionmentioning

confidence: 99%